Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
9.68
-0.78 (-7.46%)
Mar 31, 2025, 1:39 PM EDT - Market open

Nuvectis Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
6.937.526.013.350.02
Research & Development
12.9214.3812.032.45-
Operating Expenses
19.8521.918.035.790.02
Operating Income
-19.85-21.9-18.03-5.79-0.02
Interest & Investment Income
0.850.640.150-
EBT Excluding Unusual Items
-19-21.26-17.89-5.79-0.02
Other Unusual Items
--1-1.2-7.1-
Pretax Income
-19-22.26-19.09-12.89-0.02
Net Income
-19-22.26-19.09-12.89-0.02
Net Income to Common
-19-22.26-19.09-12.89-0.02
Shares Outstanding (Basic)
17161344
Shares Outstanding (Diluted)
17161344
Shares Change (YoY)
10.01%22.90%196.55%9.44%-
EPS (Basic)
-1.11-1.43-1.51-3.02-
EPS (Diluted)
-1.11-1.43-1.51-3.02-
EBIT
-19.85-21.9-18.03-5.79-0.02
Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q